NoticiasCon ayuda de IA

Xiogenix Collaboration Enhances Cellipont's Capabilities

Cellipont partners with Xiogenix to adopt Ares™ X20 system, boosting cell therapy manufacturing precision.

Priyanka Patil
Por Priyanka Patil
Asociado de marketing · Pharma Now
11 dic 2024Updated Jun 26, 2025 · 2 min de lectura
Xiogenix Collaboration Enhances Cellipont's Capabilities
https://www.constant-content.com/content-writing-service/2017/01/5-ways-you-can-collaborate-with-other-companies-and-grow-your-reach/
Reportaje con ayuda de IA
Reviewed by Priyanka Patil, Asociado de marketing · Pharma Now

Cellipont Bioservices, a leading CDMO in cell therapy, has partnered with Xiogenix to integrate the Ares™ X20 fill-and-finish system into its offerings. This advanced system automates formulation, ensures precise temperature control, and processes containers efficiently, optimizing manufacturing quality and scalability.

The partnership aims to enhance Cellipont's production capabilities, ensuring high standards in cell therapy development. Darren Head, CEO of Cellipont, and Rachel Bahr, CEO of Xiogenix, both emphasized the collaboration's potential to innovate biopharmaceutical manufacturing and accelerate the delivery of cutting-edge therapies to market.

Priyanka Patil
Written by
Priyanka Patil
Asociado de marketing · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Cargando la conversación…

Más de Pharma News

Todos los artículos →